

In the claims

The following amendments are made with respect to the claims in the International application PCT/GB2004/004459.

This listing of claims will replace all prior versions and listings of claims in this application.

1 (currently amended). ~~Use of ifenprodil for the manufacture of a medicament~~ A method for the treatment of pain wherein said method comprises the administration of ifenprodil to a patient in need of such treatment.

2 (currently amended). ~~[[Use]]~~ The method according to claim 1, for the treatment of intermittent or episodic pain experienced by a patient undergoing chronic pain treatment.

3 (currently amended). ~~Use according to claims 1 or claim 2~~ The method according to claim 1, wherein the pain is chronic benign pain.

4 (currently amended). ~~[[Use]]~~ The method according to claim 3, wherein the pain is related to a musculoskeletal, visceral or headache condition.

5 (currently amended). ~~[[Use]]~~ The method according to claim 4, wherein the condition is osteoarthritis, chronic pancreatitis or chronic migraine.

6 (currently amended). ~~[[Use]]~~ The method according to claim 2, wherein the pain is episodic or breakthrough pain in cancer.

7 (currently amended). ~~[[Use]]~~ The method according to claim 1, wherein the pain is acute pain.

8 (currently amended). ~~[[Use]]~~ The method according to claim 1, wherein the pain is post-operative pain.

9 (currently amended). ~~Use according to any preceding claim~~ The method according to claim 1, wherein the ifenprodil is in the form of either or both *threo* enantiomers.

10 (currently amended). ~~[[Use]]~~ The method according to claim 9, wherein the ifenprodil is (-)-*threo*-ifenprodil.

11 (currently amended). ~~Use according to any preceding claim wherein the medicament is for administration~~ The method according to claim 1, where the administration is done via a route that avoids first-pass metabolism.

12 (currently amended). ~~[[Use]]~~ The method according to claim 11, wherein the route is sublingual.

13 (currently amended). ~~[[Use]]~~ The method according to claim 11, wherein the route is intranasal.

14 (currently amended). ~~[[Use]]~~ The method according to claim 11, wherein the route is dermal.

15 (currently amended). ~~Use according to any of claims 11 to 14~~ The method according to claim 11, wherein the ~~medicament~~ ifenprodil is in the form of a unit dosage containing less than 60 mg ifenprodil.

16 (original). A composition suitable for intranasal delivery, which comprises an aqueous solution of ifenprodil, a solubility enhancer and a humectant.

17 (currently amended). ~~[[A]]~~ The composition according to claim 16, wherein the ifenprodil is (-)-*threo*-ifenprodil.

18 (currently amended). ~~[[A]]~~ The composition according to claim 17, wherein the ifenprodil is (-)-*erythro*-ifenprodil.